Mr. Andre Godin reports

INTELGENX TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON MARCH 21, 2024 – CONFERENCE CALL TO FOLLOW

IntelGenx Technologies Corp. will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.

An accompanying conference call will be hosted by Dwight Gorham, chief executive officer, and Andre Godin, president and chief financial officer, to discuss the results and provide a business update. Details of the conference call and webcast are provided herein.

Fourth quarter and full year 2023 results conference call details

Date:  Thursday, March 21, 2024

Time:  8:30 a.m. ET

Live call:   1-888-506-0062 (Canada and the United States); 1-973-528-0011 (international)

Access code:  321268

The call will also be broadcast live and archived on the company's website under webcasts in the investors section.

About IntelGenx Technologies Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D (research and development), analytical method development, clinical monitoring, IP, and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

We seek Safe Harbor.